MNPR — Monopar Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $274.94m
- $214.73m
- 38
- 24
- 63
- 36
Annual income statement for Monopar Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 6.51 | 9.13 | 10.5 | 8.83 | 16.2 |
| Operating Profit | -6.51 | -9.13 | -10.5 | -8.83 | -16.2 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -6.3 | -9.1 | -10.5 | -8.4 | -15.6 |
| Net Income After Taxes | -6.3 | -9.1 | -10.5 | -8.4 | -15.6 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -6.3 | -9.1 | -10.5 | -8.4 | -15.6 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -6.3 | -9.1 | -10.5 | -8.4 | -15.6 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -2.88 | -3.65 | -4.13 | -3.04 | -4.11 |